We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

‘Glow-In-The-Dark’ Proteins to Help Diagnose Viral Diseases More Quickly and Easily

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)
Image: Proteins that glow bright blue or green could make disease diagnosis quicker and easier (Photo courtesy of Eindhoven University of Technology)

Despite undergoing technological advancements, most diagnostic tests for viral diseases that are highly sensitive still involve complex techniques to prepare a sample or interpret the results, making it hard to administer these tests in point-of-care settings or in locations with limited resources. Now, a team of researchers has come up with a sensitive technique that analyzes viral nucleic acids in as little as 20 minutes and can be finished in one step using “glow-in-the-dark” proteins.

Bioluminescence is a scientific phenomenon caused by a chemical reaction involving the luciferase protein that creates the luminescent, glow-in-the-dark effect. The luciferase protein has been utilized in creating sensors that emit observable light when they detect their target, making them perfect for point-of-care testing. Nonetheless, these sensors lack the high levels of sensitivity required of a clinical diagnostic test. A gene-editing method known as CRISPR has shown promise in providing this ability, although it requires multiple steps and additional specialized instruments to detect low signals from a complex and noisy sample. So, researchers at Eindhoven University of Technology (Eindhoven, Netherlands) aimed to use CRISPR-related proteins, but combine them with a bioluminescence technique whose signal could be detected with only a digital camera.

In order to ensure that there were sufficient RNA or DNA samples for analysis, the scientists employed recombinase polymerase amplification (RPA), which is a straightforward technique that operates at a constant temperature of around 100 F. The researchers devised a new technique, LUNAS (luminescent nucleic acid sensor), that is comprised of two CRISPR/Cas9 proteins specific for different neighboring parts of a viral genome each have a distinct fragment of luciferase attached to them. Upon detecting the presence of a specific viral genome being tested, the two CRISPR/Cas9 proteins bind to the designated nucleic acid sections and are drawn close to one another, enabling the complete luciferase protein to form and shine blue light in the presence of a chemical substrate.

To take into account the depletion of the substrate, the researchers utilized a control reaction that radiated green light. The presence of a positive result was indicated by a tube that changed from green to blue. The RPA-LUNAS technique successfully detected SARS-CoV-2 RNA in clinical samples obtained from nasal swabs in just 20 minutes, even at concentrations as low as 200 copies per microliter. The researchers believe that the LUNAS assay holds immense potential for quickly and efficiently detecting various other viruses.

Related Links:
Eindhoven University of Technology 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more